Category: GeoVax Recent News

IDSA’s Recommendations Reinforce GeoVax’s Phase 2 Findings: Robust T-Cell Responses, Cross-Variant Durability, and Favorable Safety Profile in Vulnerable Populations Atlanta, GA — October 29, 2025 — GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today emphasized how its recently presented Phase 2 clinical data for GEO-CM04S1, first reported at the…

Pipeline Intersects With the Vast Majority of Strategic Initiatives to Make America Safer, Stronger, and More Prosperous Atlanta, GA – September 29, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and cancers, today announced its strong support for the newly unveiled America First Global Health Strategy by…

Initiative Builds on Checkpoint Inhibitor Momentum and Landmark KEYNOTE-689 Results   ATLANTA, GA – September 24, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against cancers and infectious diseases, today announced the expansion of its oncology development strategy to include assessments of additional solid tumor targets for Gedeptin®, its…

Company Underscores Rigorous Safety Monitoring and Long History of the MVA Platform as Development of GEO-CM04S1 Advances Atlanta, GA – September 22, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines, today reaffirmed its commitment to rigorous, science-based evaluation of vaccine safety. The statement follows discussions by federal officials at…

Next-Generation Multi-Antigen COVID-19 Vaccine Demonstrates Differentiated Immune Responses in Immunocompromised Patients ATLANTA, GA, September 18, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced that it will present at the Emerging Growth Conference on Thursday, September 25, 2025. This live, interactive online…

Multi-Antigen COVID-19 Vaccine Candidate Outperforms mRNA Comparator; Enrollment Now Limited to GEO-CM04S1 Arm ATLANTA, GA – September 15, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today showcased positive interim results for its lead COVID-19 vaccine candidate, GEO-CM04S1 at the XXI International Workshop…

Next-Generation Multi-Antigen COVID-19 Vaccine Demonstrates Strong Immune Responses in High-Need Patient Populations ATLANTA, GA – September 12, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today discussed positive interim clinical results for its lead COVID-19 vaccine candidate, GEO-CM04S1, presented at the 6th ESCMID…

GEO-CM04S1 Demonstrates Promise Among Most Vulnerable Immunocompromised Patients ATLANTA, GA, September 8, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced that its Chief Medical Officer and clinical collaborators will present data highlighting the cross-variant antibody and robust cellular immune responses induced…

Company to provide key updates on GEO-MVA, GEO-CM04S1, and Gedeptin® programs ATLANTA, GA, September 3, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced that its Chairman and CEO, David Dodd, will present a company overview and host investor meetings during the…

Company Underscores its Commitment to Advancing Equitable Access to Vaccines and Health Innovation on a Global Stage   Atlanta, Georgia – October 1, 2025 – GeoVax, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced its sponsorship of the 3rd Annual Dr. David Satcher Global Health…

Expands Intellectual Property Portfolio Supporting Next-Generation COVID-19 Vaccine Candidates ATLANTA, GA, August 20, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/888,131, titled “Vaccines and…

Company to Provide Key Updates on GEO-MVA and Its Mpox Vaccine Development Program ATLANTA, GA, August 18, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced that it will present at the Emerging Growth Conference on Wednesday, August 20, 2025. This live,…